198835-07-3 Usage
Description
(1r,4r,5r)-rel-tertbutyl 5hydroxy2azabicyclo[2.2.1]heptane2carboxylate is a complex carboxylate ester with a bicyclic structure that incorporates a nitrogen atom. Characterized by the presence of a tert-butyl group, a hydroxyl group, and a specific stereochemistry, this compound suggests potential for biological activity and pharmaceutical applications. Its unique three-dimensional shape, conferred by the arrangement of its atoms, may enable specific interactions within a biological context, positioning it as a promising candidate for research and development in medicinal chemistry and drug design.
Uses
Used in Pharmaceutical Industry:
(1r,4r,5r)-rel-tertbutyl 5hydroxy2azabicyclo[2.2.1]heptane2carboxylate is used as a potential pharmaceutical agent for its possible biological activity. (1r,4r,5r)-rel-tertbutyl 5hydroxy2azabicyclo[2.2.1]heptane2carboxylate's structural complexity and functional groups may allow it to interact with biological targets, making it suitable for the development of new drugs.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (1r,4r,5r)-rel-tertbutyl 5hydroxy2azabicyclo[2.2.1]heptane2carboxylate serves as a subject for studying its interactions with biological molecules. Its unique stereochemistry and functional groups can provide insights into the design of more effective and selective drugs.
Used in Drug Design:
(1r,4r,5r)-rel-tertbutyl 5hydroxy2azabicyclo[2.2.1]heptane2carboxylate is utilized in drug design to explore its potential as a lead compound. (1r,4r,5r)-rel-tertbutyl 5hydroxy2azabicyclo[2.2.1]heptane2carboxylate's specific three-dimensional shape and functional groups may be optimized to enhance its pharmacological properties, such as potency, selectivity, and bioavailability.
Check Digit Verification of cas no
The CAS Registry Mumber 198835-07-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,8,8,3 and 5 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 198835-07:
(8*1)+(7*9)+(6*8)+(5*8)+(4*3)+(3*5)+(2*0)+(1*7)=193
193 % 10 = 3
So 198835-07-3 is a valid CAS Registry Number.
198835-07-3Relevant articles and documents
RET inhibitor and pharmaceutical composition and application thereof
-
Paragraph 0335-0338, (2021/10/27)
The invention belongs to the field of medicines, and relates to an RET inhibitor and a pharmaceutical composition and application thereof. Specifically, the invention relates to a compound as shown in a formula (I), or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug of the compound as shown in the formula (I). The invention also relates to pharmaceutical compositions comprising the compounds, and uses of the compounds and pharmaceutical compositions thereof in the preparation of a medicine which is especially used for the treatment and prevention of RET-related diseases and disorders, including cancers, irritable bowel syndrome and/or pain associated with irritable bowel syndrome.
Synthesis and biological evaluation of pyrimidine derivatives with diverse azabicyclic ether/amine as novel GPR119 agonist
Yang, Zunhua,Fang, Yuanying,Park, Haeil
, p. 2515 - 2519 (2017/05/10)
A class of novel pyrimidine derivatives bearing diverse conformationally restricted azabicyclic ether/amine were designed, synthesized and evaluated for their GPR119 agonist activities against type 2 diabetes. Most compounds exhibited superior hEC50
Synthesis of novel azanorbornylpurine derivatives
H?ebabecky, Hubert,Dejmek, Milan,Dra?ínsky, Martin,?ála, Michal,Leyssen, Pieter,Neyts, Johan,Kaniaková, Martina,Kr?ek, Jan,Nencka, Radim
experimental part, p. 1286 - 1298 (2012/02/15)
Azanorbornylpurine derivatives were prepared by Mitsunobu reaction of appropriate hydroxyazanorbornane derivative with 6-chloropurine or construction of purine base at azanorbornylamines. The prepared target compounds were evaluated for antiviral activity and effect on neuronal and muscle nicotinic acetylcholine receptors.
